{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:26Z","timestamp":1790085686801,"version":"4.0.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer remains one of the leading causes of cancer-related death worldwide, with particularly high incidence in East Asia. Despite improvements in surgical resection and perioperative chemotherapy, patients with advanced or metastatic disease face a poor prognosis. The arrival of ICIs, especially anti-PD-1 antibodies such as nivolumab, has offered new treatment options. The landmark CheckMate 649 trial showed that adding nivolumab to chemotherapy significantly improves overall survival in advanced GC, gastroesophageal junction cancer, and esophageal adenocarcinoma. However, longer-term follow-up analyses have made it clear that a substantial proportion of patients either do not respond initially or relapse after an initial response. Thus, there is an urgent need to understand the mechanisms behind immunotherapy resistance.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1913444","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:14:00Z","timestamp":1790082840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CLEVER-1+ tumor-associated macrophages in gastric cancer immunotherapy resistance: integrating metabolic reprogramming and immunosuppression"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Chengdu Seventh People \u2018 s Hospital (Affiliated Cancer Hospital of Chengdu Medical College)","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"GI Medicine, Binhai Hospital Of Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijue","family":"Qiu","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine and Life Sciences, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01634-6","article-title":"Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results","volume":"28","author":"Lin","year":"2025","journal-title":"Gastric Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","article-title":"Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1706744","article-title":"Tumor associated macrophages in gastric cancer dual roles in immune evasion and clinical implications for targeted therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-025-07644-7","article-title":"SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06683-4","article-title":"Clever-1 positive macrophages in breast cancer","volume":"195","author":"Mutka","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013145","article-title":"CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer","volume":"13","author":"Xiang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011080","article-title":"Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer","volume":"13","author":"Yu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-3016","article-title":"Immunotherapeutic blockade of macrophage Clever-1 reactivates the CD8(+) T-cell response against immunosuppressive tumors","volume":"25","author":"Viitala","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-21-0840","article-title":"Nonclinical characterization of Bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers","volume":"21","author":"Hollm\u00e9n","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101307","article-title":"Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I\/II first-in-human MATINS trial","volume":"4","author":"Rannikko","year":"2023","journal-title":"Cell Rep Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-4862","article-title":"Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I\/II clinical trial","volume":"27","author":"Virtakoivu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2008.07.025","article-title":"TGF-beta: a master of all T cell trades","volume":"134","author":"Li","year":"2008","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7150\/thno.110544","article-title":"Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy","volume":"15","author":"Prince","year":"2025","journal-title":"Theranostics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15212680","article-title":"Intratumoral SPP1(+)BCL2A1(+) tumor-associated macrophages predict poor response to PD1 blockade","volume":"15","author":"Lai","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26883","DOI":"10.1038\/s41598-025-10301-w","article-title":"Single-cell RNA sequencing analysis revealed the immunosuppressive remodeling of tumor-associated macrophages mediated by the MIF-CD74 axis in gastric cancer","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939896","article-title":"Clever-1\/Stabilin-1 regulates lymphocyte migration within lymphatics and leukocyte entrance to sites of inflammation","volume":"39","author":"Karikoski","year":"2009","journal-title":"Eur J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1096897","article-title":"Macrophage scavenger receptors: Tumor support and tumor inhibition","volume":"12","author":"Kazakova","year":"2022","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.09.029","article-title":"FABP5(+) lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity","volume":"82","author":"Yang","year":"2025","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1639823","article-title":"The impact of aberrant lipid metabolism on the immune microenvironment of gastric cancer: a mini review","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002548","article-title":"S100A4 enhances protumor macrophage polarization by control of PPAR-\u03b3-dependent induction of fatty acid oxidation","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-025-01840-5","article-title":"SLC2A1(+) tumour-associated macrophages spatially control CD8(+) T cell function and drive resistance to immunotherapy in non-small-cell lung cancer","volume":"28","author":"Wang","year":"2026","journal-title":"Nat Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80721","article-title":"Arginase 1 is a key driver of immune suppression in pancreatic cancer","volume":"12","author":"Menjivar","year":"2023","journal-title":"Elife"},{"key":"B23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12967-025-06276-x","article-title":"IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03425-w","article-title":"USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells","volume":"44","author":"You","year":"2025","journal-title":"Oncogene"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.20251","article-title":"Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K\/AKT\/mTOR-PD-L1 axis to overcome immune escape in gastric cancer","volume":"13","author":"Duan","year":"2025","journal-title":"PeerJ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115262","article-title":"Inhibition of Skp2 enhances anti-tumor immunity of macrophages by regulating CD47 in gastric cancer","volume":"163","author":"Hu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10555-025-10269-z","article-title":"Novel immunotherapy for gastric cancer: targeting the CD47-SIRP\u03b1 axis","volume":"44","author":"Ooki","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113224","article-title":"Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity","volume":"42","author":"Zhong","year":"2023","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-025-03335-5","article-title":"CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages","volume":"44","author":"Xu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.01.012","article-title":"Uncovering mechanisms underlying complement-mediated cancer immune evasion","volume":"32","author":"O'Connell","year":"2024","journal-title":"Mol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/1750743x.2026.2617035","article-title":"Clinical optimization of bexmarilimab as a myeloid checkpoint therapy","volume":"17","author":"Karthikeyan","year":"2025","journal-title":"Immunotherapy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.233","article-title":"LTBR acts as a novel immune checkpoint of tumor-associated macrophages for cancer immunotherapy","volume":"3","author":"Wang","year":"2024","journal-title":"Imeta"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1913444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:14:00Z","timestamp":1790082840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1913444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1913444"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1913444","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1913444"}}